81.19 USD
-3.09 (-3.67%)
81.19 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MLAB. MLAB was compared to 57 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of MLAB while its profitability can be described as average. MLAB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MLAB had negative earnings in the past year.
MLAB had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
MLAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MLAB has a Return On Assets of -0.37%. This is in the better half of the industry: MLAB outperforms 66.67% of its industry peers.
MLAB has a Return On Equity of -0.88%. This is in the better half of the industry: MLAB outperforms 68.42% of its industry peers.
MLAB has a better Return On Invested Capital (3.11%) than 64.91% of its industry peers.
MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 13.75%.
The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
MLAB's Operating Margin of 6.13% is fine compared to the rest of the industry. MLAB outperforms 61.40% of its industry peers.
In the last couple of years the Operating Margin of MLAB has grown nicely.
MLAB has a Gross Margin of 62.15%. This is amongst the best in the industry. MLAB outperforms 82.46% of its industry peers.
In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
Compared to 1 year ago, MLAB has more shares outstanding
Compared to 5 years ago, MLAB has more shares outstanding
MLAB has a better debt/assets ratio than last year.
2.2 Solvency
MLAB has an Altman-Z score of 1.29. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MLAB (1.29) is worse than 61.40% of its industry peers.
MLAB has a debt to FCF ratio of 4.69. This is a neutral value as MLAB would need 4.69 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.69, MLAB is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
MLAB has a Debt/Equity ratio of 0.95. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.95, MLAB is doing worse than 78.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.29 |
ROIC/WACC0.29
WACC10.55%
2.3 Liquidity
MLAB has a Current Ratio of 2.02. This indicates that MLAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.02, MLAB is in line with its industry, outperforming 40.35% of the companies in the same industry.
MLAB has a Quick Ratio of 1.44. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
MLAB has a worse Quick ratio (1.44) than 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.68%.
MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.39%.
The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 231.94% on average per year.
Based on estimates for the next years, MLAB will show a small growth in Revenue. The Revenue will grow by 4.49% on average per year.
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MLAB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 49.85, the valuation of MLAB can be described as expensive.
MLAB's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (23.92), we can say MLAB is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MLAB is valued cheaper than 89.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MLAB is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.02 | ||
| EV/EBITDA | 15.13 |
4.3 Compensation for Growth
MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MLAB may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y382.35%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
With a yearly dividend of 0.76%, MLAB is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.09, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.92, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-222.26%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
81.19
-3.09 (-3.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.73%
Inst Owner Change0.08%
Ins Owners5.44%
Ins Owner Change3.69%
Market Cap448.17M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (19.35%)
Short Float %5.43%
Short Ratio2.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)6
Avg EPS beat(12)229.18%
EPS beat(16)8
Avg EPS beat(16)167.02%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)7.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.74%
EPS NY rev (1m)0%
EPS NY rev (3m)9.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.85 | ||
| P/S | 1.83 | ||
| P/FCF | 12.02 | ||
| P/OCF | 10.87 | ||
| P/B | 2.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.13 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.63
Fwd EY2.01%
FCF(TTM)6.76
FCFY8.32%
OCF(TTM)7.47
OCFY9.2%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.29 |
F-Score5
WACC10.55%
ROIC/WACC0.29
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
What is the valuation status of MESA LABORATORIES INC (MLAB) stock?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
What is the financial health of MESA LABORATORIES INC (MLAB) stock?
The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.
Can you provide the expected EPS growth for MLAB stock?
The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 2707.43% in the next year.